Marshall Fordyce Sells 46,250 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

July 10, 2026 by InsiderTrades.com

Key Points

CEO Marshall Fordyce sold 46,250 Vera Therapeutics shares at an average price of $42.30, totaling about $1.96 million. The sale reduced his ownership by 23.33% and was made under a pre-arranged Rule 10b5-1 plan.
Vera Therapeutics has been buoyed by positive catalyst news, including FDA accelerated approval of Trutakna and multiple analyst price-target hikes. HC Wainwright and Needham both set targets at $125, while Wedbush and others also raised expectations.
The stock recently traded around $42.45, near its 52-week range midpoint, while the company reported a wider-than-expected quarterly loss of ($1.69) EPS. Despite losses, institutional ownership remains very high at 99.21%.

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) CEO Marshall Fordyce sold 46,250 shares of the company's stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company's stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

3 Biotech Firms With Major Potential Catalysts in the Coming Months

Marshall Fordyce also recently made the following trade(s):

On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The stock was sold at an average price of $37.93, for a total value of $701,705.00.
On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $36.74, for a total value of $679,690.00.
On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55.

Vera Therapeutics Stock Up 0.0%

NASDAQ VERA opened at $42.45 on Friday. The business has a fifty day moving average price of $36.50 and a two-hundred day moving average price of $41.10. The stock has a market capitalization of $3.05 billion, a PE ratio of -7.66 and a beta of 0.92. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64.

Analysts Can't Get Enough of These Little-Known Biopharma Stocks

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same quarter in the prior year, the company earned ($0.81) EPS. Equities analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current fiscal year.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

Positive Sentiment: The FDA’s accelerated approval of Trutakna is a major commercial milestone for Vera Therapeutics and the clearest driver behind the stock’s recent strength. FDA grants accelerated approval to Vera Therapeutics' Trutakna
Positive Sentiment: HC Wainwright raised its price target to $125 and kept a buy rating, signaling confidence in Vera’s launch opportunity and longer-term upside. Vera Therapeutics had its price target raised by HC Wainwright from $110.00 to $125.00.
Positive Sentiment: Wedbush increased its price target to $43, reflecting continued analyst support even after the FDA news-driven rally. Vera Therapeutics had its price target raised by Wedbush from $35.00 to $43.00.
Neutral Sentiment: The company announced a planned transition in its chief regulatory officer role, with Nancy Boman appointed and William Turner set to retire; this looks like routine leadership succession rather than a major strategic shift. Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Negative Sentiment: CEO Marshall Fordyce sold 46,250 shares under a pre-arranged 10b5-1 plan, a move that may weigh slightly on sentiment even though it was scheduled in advance. SEC filing for CEO Marshall Fordyce stock sale

Hedge Funds Weigh In On Vera Therapeutics

Several institutional investors have recently added to or reduced their stakes in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Vera Therapeutics by 7.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company's stock worth $753,000 after buying an additional 2,210 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company's stock valued at $2,354,000 after acquiring an additional 17,907 shares in the last quarter. Jane Street Group LLC increased its stake in shares of Vera Therapeutics by 297.1% in the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company's stock valued at $999,000 after acquiring an additional 62,678 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company's stock valued at $7,316,000 after acquiring an additional 262,805 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company's stock valued at $1,188,000 after acquiring an additional 825 shares during the period. 99.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. William Blair reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 target price on shares of Vera Therapeutics in a research report on Friday, May 15th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a report on Wednesday. TD Cowen boosted their price target on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Vera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $84.58.

View Our Latest Stock Analysis on Vera Therapeutics

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.